Collagen Type XVIII Assay
AssigneeNordic Bioscience A/S
InventorsTina Manon-Jensen, Morten Karsdal
Life of this patent
Estimating the term…
Abstract
The present invention relates to an antibody, wherein the antibody is specifically reactive with short isoform collagen type XVIII, but does not react with intermediate isoform collagen type XVIII or with long isoform collagen type XVIII. The invention also relates to the use of the antibody in a method of immunoassay for detecting or quantitating short isoform collagen type XVIII, where the method may be used to evaluate haemophilic disease.
Claims20
An antibody specifically reactive with a short isoform of collagen type XVIII, wherein said antibody does not react with an intermediate isoform of collagen type XVIII or with a long isoform of collagen type XVIII.
A method of immunoassay for detecting or quantitating in a sample a short isoform of collagen type XVIII, wherein said method comprises contacting the sample of the short isoform of collagen type XVIII with an antibody specifically reactive with the short isoform of collagen type XVIII, wherein said antibody does not react with an intermediate isoform of collagen type XVIII or with a long isoform of collagen type XVIII, and determining an amount of binding of said antibody.
A method for evaluating the efficacy of a drug for treating a haemophilic disease, wherein the method comprises using a method of immunoassay for quantitating in a sample comprising a short isoform collagen type XVIII an amount of collagen type XVIII in at least two samples obtained from a subject at a first time point and at at least one subsequent time point during a period of administration of the drug to the subject,
- wherein said method of immunoassay comprises contacting the sample comprising said short isoform collagen type XVIII with an antibody specifically reactive with the short isoform collagen type XVIII,
- wherein said antibody does not react with an intermediate isoform of collagen type XVIII or with a long isoform of collagen type XVIII, and determining an amount of binding of said antibody, and
- wherein a reduction in the amount of collagen type XVIII from the first time point to the at least one subsequent time point during the period of administration of the drug is indicative of an efficacious drug for treating a haemophilic disease.
An assay kit for determining the quantity of short isoform collagen type XVIII, the kit comprising an antibody specifically reactive with short isoform collagen type XVIII, wherein said antibody does not react with intermediate isoform collagen type XVIII or with long isoform collagen type XVIII, and at least one of:
- a streptavidin coated 96 well plate;
- a peptide which is reactive with said antibody, which may be a biotinylated peptide H2N-EPERISEEVG-L-Biotin (SEQ ID NO:
- 5), wherein L is an optional linker;
- an optionally biotinylated secondary antibody for use in a sandwich immunoassay;
- a calibrator peptide comprising the N-terminal sequence H2N-EPERISEEVG (SEQ ID NO:
- 6);
- an antibody HRP labeling kit;
- an antibody radiolabeling kit;
- or
- an assay visualization kit.
Dependencies are inferred from the claim text.